



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Chu et al.

Serial No.: 10/665,936

Confirmation No.: Unknown

Filed:

September 19, 2003

For:

DELIVERY OF

THERAPEUTICS TO TREAT

ANEURYSMS

ത ത ത ത ത ത ത ത ത ത ത ത

Group Art Unit: Unknown

Examiner:

Unknown

Customer Number:

28390

MAIL STOP DD Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir or Madame:

CERTIFICATE OF MAILING

37 CFR 1.8

I hereby certify that this correspondence is being deposited on **December 15, 2003** with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

12/15/0

Esther Marques

INFORMATION DISCLOSURE STATEMENT

Date

The Applicants, and the Attorney who signs below on the basis of the information supplied by the inventor and the information in his file, submit herewith patents, publications, or other information of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

While the information submitted in this Information Disclosure Statement may be material pursuant to 37 CFR § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is prior art for this invention unless specifically designated as such.

In accordance with 37 CFR § 1.97, this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other possibly material information as defined under 37 CFR § 1.56(a) exists.

The patents and/or publications submitted herewith are set forth on the attached Forms PTO-SB08A and SB08B.

While we believe that no fee is due, if the sum of \$180.00 is due under 37 CFR § 1.17(p) pursuant to § 1.97, the Commissioner is hereby authorized to charge

1

241737 1

this fee, and any other fee necessary to make this submission timely, to the Deposit Account No. 20-0782/P1768 (MEDT/0024/SB).

Respectfully submitted,

Sarah J. Brashears

Registration No. 38,087 Telephone: (650) 330-2310

Facsimile: (650) 330-2314 Attorney for Applicant(s)

2

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

10/665,936

Chu et al.

Unknown

August 18, 2003

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Filing Date

Art Unit

Application Number

First Named Inventor

Complete if Known

OIL 6

DEC 17 2003

Sheet | 1

Under the Paperworn ... Under the Paperworn ... ADENABED Stitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Examiner Name Unknown P1768 (MEDT/0024) of 3 Attorney Docket Number

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	^{US-} 2002/0065546	05/30/2002	Machan et al.	
	2	^{US-} 5,538,504	07/23/1996	SciMed Life Systems, Inc.	
	3	^{US-} 5,670,161	09/23/1997	Healy et al.	
	4	^{US-} 5,834,449	12/10/1998	The Research Foundation of State	University of
		US-		New York; Washington University	
	5	^{US-} 6,159,239	12/12/2000	Prodesco, Inc.	
	6	^{US-} 6,190,353	02/20/2001	TransVascular, Inc.	
	7	^{US-} 6,302,870	10/16/2001	Precision Vascular Systems, Inc.	
	8	^{US-} 6,344,035	02/05/2002	Surmodics, Inc.	
	9	^{US-} 6,348,050	02/19/2002	Medtronic, Inc.	
	10	^{US-} 6,364,903	04/02/2002	Meadox Medicals, Inc.	
	11	^{US-} 6,368,346	04/09/2002	American Medical Systems, Inc.	
	12	^{US-} 6,371,970	04/16/2002	Incept LLC	
	13	^{US-} 6,376,742	04/23/2002	Zdrahala et al.	
	14	US- 6,387,121	05/14/2002	Inflow Dynamics Inc.	
	15	^{US-} 6,451,373	09/17/2002	Advanced Cardiovascular Systems	, Inc.
	16	^{US-} 6,506,410	01/14/2003	Kong Kook Pharmaceutical Co., Lt	d.
	17	^{US-} 6,514,515	02/04/2003	Tepha, Inc.	
	18	^{US-} 6,531,154	03/11/2003	Brown University Research Found	ation

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T	
	1	WO-02/15824-A2	02/28/2002	Kensey Nash Corporation			
	ļ					L	
	ļ _					-	
 						L	
						ı	

Examiner		 Date	
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

decline Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substition	te for form 1449/PTO	duction Act of 1995, no persons at		Complete if Known			
OFTER	10 10 10 11 1440 170			Application Number	10/665,936	—,	
INF	ORMATION	DIS	CLOSURE	Filing Date	September 19, 2003		
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Chu et al.		
	(llea se many cha	ate se r	acaecand	Art Unit	Unknown		
(Use as many sheets as necessary)				Examiner Name	Unknown		
Sheet	2	of	3	Attorney Docket Number	P1768 (MEDT/0024)		

			-
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	"Beta-Blockers (Beta-Adrenergic Blocking Drugs)." <u>Texas Heart Institute Heart Information Center.</u> 18 March 2003 http://www.tmc.edu/thi/betameds.html .	
	2	"Beta Blockers." <u>Cardiac Consultants.</u> 18 March 2003 http://www.cardiacconsultants.com/beta.htm .	
	3	"Beta Blockers (Beta-Adrenergic Bockers, Beta 1 Blockers, Beta 2 Blockers, B-Blockers)." <u>HeartCenterOnline</u> . 18 March 2003 http://www.heartcenteronline.com/myheartdr/common/articles.cfm?ARTID=331 .	
	4	"beta-blocker." <u>Bartleby.com.</u> 18 March 2003 http://www.bartleby.com/65/be/beta-b.html .	
	5	Slaiby, Jeffrey M. et al. "Expansion of aortic aneurysms is reduced by proparanolol in a hypertensive rat model." <u>Journal of Vascular Surgery</u> . 21 January 2002 .">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/searchDBfor=art&a>.">http://www.harcourthealth.com/scripts/om.dll/searchDBfor=art&a>.">http://www.harcourthealth.co	
•	6	Vine, N. et al. "Metalloproteinases in degenerative aortic disease." <u>Clinical Science</u> 1991, 81: 233-239.	
	7	Goodman, Louis Sanford and Albert Gilman. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001.	
	8	Jackson, Edwin K. "Renin and Angiotensin." 809-835.	
	9	Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." <u>Journal of Vascular Surgery</u> . May 2001, 33, No. 5: 1057-1064.	
	10	Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." <u>Annals New York Academy of Sciences</u> 2002, 961: 96-105.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons are Substitute for sorm 1449/PTO	Complete if Known			
RADEMEST TO THE TOTAL PROPERTY OF THE PARTY	Application Number	10/665,936		
INFORMATION DISCLOSURE	Filing Date	September 19, 2003		
STATEMENT BY APPLICANT	First Named Inventor	Chu et al.		
(Use as many sheets as necessary)	Art Unit	Unknown		
(Use as many sheets as necessary)	Examiner Name	Unknown		
Sheet 3 of 3	Attorney Docket Number	PA1768 (MEDT/0024)		

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	11	Griffith, Linda G. "Emerging Design Principles in Biomaterials and Scaffolds or Tissue Engineering." Annals New York Academy of Sciences 2002, 961: 83-95.			
	12	Ochoa, Erin R. et al. "An Overview of the Pathology and Approaches to Tissue Engineering." Annals New York Academy of Sciences 2002, 979: 10-26.			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.